Summary
Global Markets Direct’s, ‘Acute Pain - Pipeline Review, H2 2016’, provides an overview of the Acute Pain pipeline landscape.
The report provides comprehensive information on the therapeutics under development for Acute Pain, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Acute Pain and features dormant and discontinued projects.
Global Markets Direct’s report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct’s proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.
The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.
Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.
Scope
- The report provides a snapshot of the global therapeutic landscape of Acute Pain
- The report reviews pipeline therapeutics for Acute Pain by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Acute Pain therapeutics and enlists all their major and minor projects
- The report assesses Acute Pain therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Acute Pain
Reasons to buy
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Acute Pain
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Acute Pain pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Companies Mentioned
AcelRx Pharmaceuticals, Inc.
Adynxx, Inc.
Amorsa Therapeutics Inc.
AnaBios Corporation
Anavex Life Sciences Corp.
AngioChem Inc.
Antibe Therapeutics, Inc.
AskAt Inc.
Cara Therapeutics, Inc.
Centrexion Therapeutics Corp
Charleston Laboratories, Inc.
ChironWells GmbH
Crescita Therapeutics Inc.
Cytogel Pharma, LLC
Dompe Farmaceutici S.p.A.
Grunenthal GmbH
Iroko Pharmaceuticals, LLC
KemPharm, Inc.
KPI Therapeutics, Inc.
Laboratorios Del Dr. Esteve S.A.
Mallinckrodt Plc
Nanomerics Ltd
Nanotherapeutics, Inc.
Orbis Biosciences Inc
Orexo AB
Orion Oyj
Pacira Pharmaceuticals, Inc.
Phosphagenics Limited
Recro Pharma, Inc.
Scilex Pharmaceuticals, Inc.
Shulov Innovative Science Ltd.
Syntrix Biosystems, Inc.
Thar Pharmaceuticals, Inc.
Trevena, Inc.
Yungjin Pharm. Co., Ltd.
'
Table of Contents
Table of Contents 2
List of Tables 6
List of Figures 7
Introduction 8
Global Markets Direct Report Coverage 8
Acute Pain Overview 9
Therapeutics Development 10
Pipeline Products for Acute Pain - Overview 10
Pipeline Products for Acute Pain - Comparative Analysis 11
Acute Pain - Therapeutics under Development by Companies 12
Acute Pain - Therapeutics under Investigation by Universities/Institutes 16
Acute Pain - Pipeline Products Glance 17
Late Stage Products 17
Clinical Stage Products 18
Early Stage Products 19
Unknown Stage Products 20
Acute Pain - Products under Development by Companies 21
Acute Pain - Products under Investigation by Universities/Institutes 25
Acute Pain - Companies Involved in Therapeutics Development 26
AcelRx Pharmaceuticals, Inc. 26
Adynxx, Inc. 27
Amorsa Therapeutics Inc. 28
AnaBios Corporation 29
Anavex Life Sciences Corp. 30
AngioChem Inc. 31
Antibe Therapeutics, Inc. 32
AskAt Inc. 33
Cara Therapeutics, Inc. 34
Centrexion Therapeutics Corp 35
Charleston Laboratories, Inc. 36
ChironWells GmbH 37
Crescita Therapeutics Inc. 38
Cytogel Pharma, LLC 39
Dompe Farmaceutici S.p.A. 40
Grunenthal GmbH 41
Iroko Pharmaceuticals, LLC 42
KemPharm, Inc. 43
KPI Therapeutics, Inc. 44
Laboratorios Del Dr. Esteve S.A. 45
Mallinckrodt Plc 46
Nanomerics Ltd 47
Nanotherapeutics, Inc. 48
Orbis Biosciences Inc 49
Orexo AB 50
Orion Oyj 51
Pacira Pharmaceuticals, Inc. 52
Phosphagenics Limited 53
Recro Pharma, Inc. 54
Scilex Pharmaceuticals, Inc. 55
Shulov Innovative Science Ltd. 56
Syntrix Biosystems, Inc. 57
Thar Pharmaceuticals, Inc. 58
Trevena, Inc. 59
Yungjin Pharm. Co., Ltd. 60
Acute Pain - Therapeutics Assessment 61
Assessment by Monotherapy Products 61
Assessment by Combination Products 62
Assessment by Target 63
Assessment by Mechanism of Action 66
Assessment by Route of Administration 69
Assessment by Molecule Type 71
Drug Profiles 73
(acetaminophen + benzhydrocodone hydrochloride) IR - Drug Profile 73
(acetaminophen + hydrocodone bitartarate) ER - Drug Profile 79
(acetaminophen + tramadol hydrochloride) SR - Drug Profile 81
(buprenorphine hydrochloride + naloxone hydrochloride) - Drug Profile 82
(celecoxib + tramadol hydrochloride) - Drug Profile 83
AAT-076 - Drug Profile 85
alfentanil hydrochloride - Drug Profile 86
AMS-410 FA - Drug Profile 87
ANAVEX-1037 - Drug Profile 88
ANAVEX-1066 - Drug Profile 89
ANAVEX-1067 - Drug Profile 90
ANAVEX-1079 - Drug Profile 91
ANAVEX-1519 - Drug Profile 92
ANG-2002 - Drug Profile 93
ARX-04 - Drug Profile 94
ATB-352 - Drug Profile 99
AYX-1 - Drug Profile 100
BBI-11008 - Drug Profile 102
celecoxib - Drug Profile 103
CL-108 - Drug Profile 104
CR-4056 - Drug Profile 106
Cyt-1010 - Drug Profile 107
dexmedetomidine hydrochloride - Drug Profile 109
DF-2593A - Drug Profile 112
difelikefalin - Drug Profile 113
Drug for Acute Pain - Drug Profile 121
ECP-1014 - Drug Profile 122
ET-1 - Drug Profile 123
FY-101C - Drug Profile 124
FY-103B - Drug Profile 125
grapiprant - Drug Profile 126
HPI-201 - Drug Profile 128
HS-731 - Drug Profile 129
ibuprofen - Drug Profile 130
ibuprofen - Drug Profile 131
ibuprofen - Drug Profile 132
ketamine hydrochloride - Drug Profile 133
lidocaine hydrochloride - Drug Profile 135
meloxicam - Drug Profile 136
meloxicam - Drug Profile 139
meloxicam ER - Drug Profile 140
Monoclonal Antibody to Inhibit TGF-Beta-1 for Acute Pain and Chronic Pancreatitis Pain - Drug Profile 141
MR-309 - Drug Profile 142
NM-0127 - Drug Profile 144
oliceridine - Drug Profile 145
Omnitram - Drug Profile 150
Peptides to Target TRPV1 for Pain and Itch - Drug Profile 151
prednisone - Drug Profile 152
Prostatic Acid Phosphatase - Drug Profile 153
RO-656570 - Drug Profile 154
Small Molecule to Block Nav1.9 Channel for Pain - Drug Profile 155
Small Molecules to Block Nav 1.7 for Pain - Drug Profile 156
Small Molecules to Block Nav 1.8 for Pain - Drug Profile 157
Synthetic Peptides to Target Mu Opioid Receptor and Delta Opioid Receptor for Pain - Drug Profile 158
T-109 - Drug Profile 159
tapentadol hydrochloride - Drug Profile 160
TRV-734 - Drug Profile 162
U-2902 - Drug Profile 164
VPX-595 - Drug Profile 166
ZEP-3 - Drug Profile 167
Acute Pain - Dormant Projects 169
Acute Pain - Discontinued Products 176
Acute Pain - Product Development Milestones 178
Featured News & Press Releases 178
Appendix 189
Methodology 189
Coverage 189
Secondary Research 189
Primary Research 189
Expert Panel Validation 189
Contact Us 189
Disclaimer 190
List of Tables
Number of Products under Development for Acute Pain, H2 2016 14
Number of Products under Development for Acute Pain - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 17
Number of Products under Development by Companies, H2 2016 (Contd..1) 18
Number of Products under Development by Companies, H2 2016 (Contd..2) 19
Number of Products under Investigation by Universities/Institutes, H2 2016 20
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Development, H2 2016 23
Comparative Analysis by Unknown Stage Development, H2 2016 24
Products under Development by Companies, H2 2016 25
Products under Development by Companies, H2 2016 (Contd..1) 26
Products under Development by Companies, H2 2016 (Contd..2) 27
Products under Development by Companies, H2 2016 (Contd..3) 28
Products under Investigation by Universities/Institutes, H2 2016 29
Acute Pain - Pipeline by AcelRx Pharmaceuticals, Inc., H2 2016 30
Acute Pain - Pipeline by Adynxx, Inc., H2 2016 31
Acute Pain - Pipeline by Amorsa Therapeutics Inc., H2 2016 32
Acute Pain - Pipeline by AnaBios Corporation, H2 2016 33
Acute Pain - Pipeline by Anavex Life Sciences Corp., H2 2016 34
Acute Pain - Pipeline by AngioChem Inc., H2 2016 35
Acute Pain - Pipeline by Antibe Therapeutics, Inc., H2 2016 36
Acute Pain - Pipeline by AskAt Inc., H2 2016 37
Acute Pain - Pipeline by Cara Therapeutics, Inc., H2 2016 38
Acute Pain - Pipeline by Centrexion Therapeutics Corp, H2 2016 39
Acute Pain - Pipeline by Charleston Laboratories, Inc., H2 2016 40
Acute Pain - Pipeline by ChironWells GmbH, H2 2016 41
Acute Pain - Pipeline by Crescita Therapeutics Inc., H2 2016 42
Acute Pain - Pipeline by Cytogel Pharma, LLC, H2 2016 43
Acute Pain - Pipeline by Dompe Farmaceutici S.p.A., H2 2016 44
Acute Pain - Pipeline by Grunenthal GmbH, H2 2016 45
Acute Pain - Pipeline by Iroko Pharmaceuticals, LLC, H2 2016 46
Acute Pain - Pipeline by KemPharm, Inc., H2 2016 47
Acute Pain - Pipeline by KPI Therapeutics, Inc., H2 2016 48
Acute Pain - Pipeline by Laboratorios Del Dr. Esteve S.A., H2 2016 49
Acute Pain - Pipeline by Mallinckrodt Plc, H2 2016 50
Acute Pain - Pipeline by Nanomerics Ltd, H2 2016 51
Acute Pain - Pipeline by Nanotherapeutics, Inc., H2 2016 52
Acute Pain - Pipeline by Orbis Biosciences Inc, H2 2016 53
Acute Pain - Pipeline by Orexo AB, H2 2016 54
Acute Pain - Pipeline by Orion Oyj, H2 2016 55
Acute Pain - Pipeline by Pacira Pharmaceuticals, Inc., H2 2016 56
Acute Pain - Pipeline by Phosphagenics Limited, H2 2016 57
Acute Pain - Pipeline by Recro Pharma, Inc., H2 2016 58
Acute Pain - Pipeline by Scilex Pharmaceuticals, Inc., H2 2016 59
Acute Pain - Pipeline by Shulov Innovative Science Ltd., H2 2016 60
Acute Pain - Pipeline by Syntrix Biosystems, Inc., H2 2016 61
Acute Pain - Pipeline by Thar Pharmaceuticals, Inc., H2 2016 62
Acute Pain - Pipeline by Trevena, Inc., H2 2016 63
Acute Pain - Pipeline by Yungjin Pharm. Co., Ltd., H2 2016 64
Assessment by Monotherapy Products, H2 2016 65
Assessment by Combination Products, H2 2016 66
Number of Products by Stage and Target, H2 2016 68
Number of Products by Stage and Mechanism of Action, H2 2016 71
Number of Products by Stage and Route of Administration, H2 2016 74
Number of Products by Stage and Molecule Type, H2 2016 76
Acute Pain - Dormant Projects, H2 2016 173
Acute Pain - Dormant Projects (Contd..1), H2 2016 174
Acute Pain - Dormant Projects (Contd..2), H2 2016 175
Acute Pain - Dormant Projects (Contd..3), H2 2016 176
Acute Pain - Dormant Projects (Contd..4), H2 2016 177
Acute Pain - Dormant Projects (Contd..5), H2 2016 178
Acute Pain - Dormant Projects (Contd..6), H2 2016 179
Acute Pain - Discontinued Products, H2 2016 180
Acute Pain - Discontinued Products (Contd..1), H2 2016 181
List of Figures
Number of Products under Development for Acute Pain, H2 2016 14
Number of Products under Development for Acute Pain - Comparative Analysis, H2 2016 15
Number of Products under Development by Companies, H2 2016 16
Comparative Analysis by Late Stage Development, H2 2016 21
Comparative Analysis by Clinical Stage Development, H2 2016 22
Comparative Analysis by Early Stage Products, H2 2016 23
Assessment by Monotherapy Products, H2 2016 65
Assessment by Combination Products, H2 2016 66
Number of Products by Top 10 Targets, H2 2016 67
Number of Products by Stage and Top 10 Targets, H2 2016 67
Number of Products by Top 10 Mechanism of Actions, H2 2016 70
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2016 70
Number of Products by Top 10 Routes of Administration, H2 2016 73
Number of Products by Stage and Top 10 Routes of Administration, H2 2016 73
Number of Products by Molecule Types, H2 2016 75
Number of Products by Stage and Molecule Types, H2 2016 75
